South Korea
· Delayed Price · Currency is KRW MOA Life Plus Company Description
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea.
It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy.
It also provides health functional food and raw materials, and cosmetics. The company was formerly known as Bioleaders Corporation and changed its name to MOA Life Plus Co. Ltd. in March 2024.
MOA Life Plus Co. Ltd. was founded in 1999 and is headquartered in Yongin-Si, South Korea.
| Country | South Korea |
| Founded | 1999 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 51 |
| CEO | Park Young Chul |
Contact Details
Address: A-7, 767, Sinsu-ro Yongin-Si, 16827 South Korea | |
| Phone | 82 3 1280 9650 |
| Website | moalifeplus.com |
Stock Details
| Ticker Symbol | 142760 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Park Young Chul | Chief Executive Officer |
| Hyun-Jae Sung | Chief Financial Officer |